Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

DEXCOM, INC.

(DXCM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/26/2020 03/27/2020 03/30/2020 03/31/2020 04/01/2020 Date
250.21(c) 262.96(c) 278(c) 269.27(c) 254.81(c) Last
1 557 348 1 514 741 1 257 912 2 002 950 1 091 972 Volume
+4.55% +5.10% +5.72% -3.14% -5.37% Change
More quotes
Financials (USD)
Sales 2020 1 750 M
EBIT 2020 227 M
Net income 2020 166 M
Finance 2020 4,07 M
Yield 2020 -
Sales 2021 2 158 M
EBIT 2021 328 M
Net income 2021 263 M
Finance 2021 266 M
Yield 2021 -
P/E ratio 2020 152x
P/E ratio 2021 94,4x
EV / Sales2020 13,3x
EV / Sales2021 10,7x
Capitalization 23 339 M
More Financials
Company
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4... 
More about the company
Surperformance© ratings of DexCom, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on DEXCOM, INC.
03/30QUALCOMM : Names Heather Ace as Executive Vice President of Human Resources; Exe..
AQ
03/10DEXCOM INC : Change in Directors or Principal Officers (form 8-K)
AQ
03/06How Lipper Award-winning fund managers are playing coronavirus scare
RE
02/24DEXCOM : to Present at Cowen 40th Annual Healthcare Conference
BU
02/20DEXCOM : G6 Continuous Glucose Monitoring (CGM) System Receives CE Mark for Use ..
BU
02/17DEXCOM : G6® CGM System Now Available In Canada
AQ
02/17DEXCOM : and Companion Medical Announce Collaboration to Integrate Dexcom CGM Da..
AQ
02/17DEXCOM : Announces FDA Clearance of New Dexcom G6 Pro CGM
AQ
02/13DEXCOM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
02/13DEXCOM : 4Q Earnings Snapshot
AQ
02/13DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..
AQ
02/13DEXCOM : Reports Fourth Quarter and Fiscal Year 2019 Financial Results
BU
02/10DEXCOM, INC. : annual earnings release
01/21DEXCOM SCHEDULES FOURTH QUARTER AND : 30 p.m. Eastern Time
BU
01/13DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..
AQ
More news
News in other languages on DEXCOM, INC.
02/10DEXCOM, INC. : Veröffentlichung des Jahresergebnisses
02/10DEXCOM, INC. : publication des résultats annuels
2013DEXCOM, INC. : publication des résultats trimestriels
2012DEXCOM, INC. : publication des résultats trimestriels
More news
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | DXCM | US2521311074 | MarketScreener
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 284,32  $
Last Close Price 254,81  $
Spread / Highest target 29,5%
Spread / Average Target 11,6%
Spread / Lowest Target -27,4%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Quentin S. Blackford Chief Operating & Financial Officer
Andrew K. Balo EVP-Clinical Affairs, Regulatory Strategies
Jacob Leach Chief Technology Officer
Jay S. Skyler Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.16.49%24 664
MEDTRONIC PLC-25.86%120 856
BAXTER INTERNATIONAL INC.-5.93%41 180
HOYA CORPORATION-5.74%32 156
TERUMO CORPORATION-3.23%25 993
ZIMMER BIOMET HOLDINGS-40.12%20 891